AVaTAR MedTech
Developer of a surgical method and associated single‑use instrument kits for trileaflet semilunar valve reconstruction using autologous pericardial tissue. Activities include device design and prototyping, preclinical in vitro and in vivo evaluation, and early clinical application with a focus on pediatric and adult aortic and pulmonary valve reconstruction.
Industries
Nr. of Employees
small (1-50)
AVaTAR MedTech
Campos Salles, C1429 Buenos Aires, Argentina; +54 Lab - Parque Innovación
Products
Surgical procedure and single‑use instrument kit for trileaflet semilunar valve reconstruction
A surgical method plus a kit of instruments engineered to standardize and semi‑automate reconstruction of a trileaflet semilunar valve from the patient’s pericardium, designed for sterile single‑use deployment and to accommodate pediatric growth.
Surgical procedure and single‑use instrument kit for trileaflet semilunar valve reconstruction
A surgical method plus a kit of instruments engineered to standardize and semi‑automate reconstruction of a trileaflet semilunar valve from the patient’s pericardium, designed for sterile single‑use deployment and to accommodate pediatric growth.
Services
Provision of 3D‑printed heart simulators and remote instructor‑led training sessions using embedded cameras to train surgeons on the reconstruction procedure and device workflow.
Provision of 3D‑printed heart simulators and remote instructor‑led training sessions using embedded cameras to train surgeons on the reconstruction procedure and device workflow.
Expertise Areas
- Semilunar valve reconstruction surgery
- Pediatric cardiac surgery and growth‑accommodating valve design
- Medical device design and rapid prototyping
- Hydrodynamic in vitro testing
Key Technologies
- Autologous pericardial neo‑leaflets
- Additive manufacturing (3D printing) for device prototyping
- Injection molding with biocompatible plastics
- Pulsatile flow‑loop hydrodynamic testing
News & Updates
Media profile describing founders, device concept, clinical experience and training plans.
Participation in accelerator Demo Day and inclusion in the GRIDX portfolio.
Article discussing funding environment and noting patent filings and pre‑seed investment.
Pulsatile in vitro evaluation of trileaflet semilunar valve reconstruction published in Interact Cardiovasc Thorac Surg (2022).
Acute porcine in vivo evaluation of trileaflet semilunar valve reconstruction published in World J Pediatr Congenit Heart Surg (2023).
Clinical use of the reconstruction method reported in a case series including operative metrics and mid‑term follow‑up (reported in site content; 11 aortic and 6 pulmonary reconstructions reported).
Media profile describing founders, device concept, clinical experience and training plans.
Participation in accelerator Demo Day and inclusion in the GRIDX portfolio.
Article discussing funding environment and noting patent filings and pre‑seed investment.
Pulsatile in vitro evaluation of trileaflet semilunar valve reconstruction published in Interact Cardiovasc Thorac Surg (2022).
Acute porcine in vivo evaluation of trileaflet semilunar valve reconstruction published in World J Pediatr Congenit Heart Surg (2023).
Clinical use of the reconstruction method reported in a case series including operative metrics and mid‑term follow‑up (reported in site content; 11 aortic and 6 pulmonary reconstructions reported).